316 results
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential
8-K
EX-99.1
th3lfxkmegq r4glx5f
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
S-3ASR
uju a3npvlvsn4wonebm
8 Nov 23
Automatic shelf registration
5:25pm
8-K
EX-99.1
se9 ns7ib5
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-10.1
r8wamga8
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-10.2
xv8tms duw6glmgf
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
k8k2pl2vvs8miyupxhrv
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.1
k66rzf79uq
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.1
wewjc1pbrmvfcm wndmw
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
y0g1w iyxsj
13 Jul 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-99.1
pp4nk
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-10.1
j6lfaqbnpox 0fkvnqw
12 May 23
Entry into a Material Definitive Agreement
5:08pm